Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Eguchi S, Kimura K, Kageyama K, Tani N, Tanaka R, Nishio K, Shinkawa H, Ohira GO, Amano R, Tanaka S, Yamamoto A, Takemura S, Yashiro M, Kubo S. Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success. Anticancer Res. 2022 May; 42(5):2395-2404.
-
Balne PK, Gupta S, Zhang J, Bristow D, Faubion M, Heil SD, Sinha PR, Green SL, Iozzo RV, Mohan RR. The functional role of decorin in corneal neovascularization in vivo. Exp Eye Res. 2021 06; 207:108610.
-
Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 03; 148(3):609-621.
-
Veruva SY, Lanman TH, Isaza JE, Freeman TA, Kurtz SM, Steinbeck MJ. Periprosthetic UHMWPE Wear Debris Induces Inflammation, Vascularization, and Innervation After Total Disc Replacement in the Lumbar Spine. Clin Orthop Relat Res. 2017 May; 475(5):1369-1381.
-
Minion LE, Tewari KS. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther. 2017 Mar; 17(3):191-198.
-
Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM. Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology. 2016; 91(6):348-353.
-
Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N. RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2. Traffic. 2016 Mar; 17(3):289-300.
-
Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24.
-
Takeda K, Fukumoto S, Motoyama K, Morioka T, Mori K, Kageyama K, Sakai Y, Sato H, Suzuki M, Koyama H, Shoji T, Ishimura E, Emoto M, Furuzono T, Nakajima K, Inaba M. Injectable cell scaffold restores impaired cell-based therapeutic angiogenesis in diabetic mice with hindlimb ischemia. Biochem Biophys Res Commun. 2014 Nov 7; 454(1):119-24.
-
Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 1; 20(23):5956-63.